Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

PSE Product Makes “Highly” Tamper-Resistant Claim With 100% Out Of Reach

This article was originally published in The Tan Sheet

Executive Summary

Westport Pharmaceuticals says a claim of being “highly” resistant to PSE-extraction distinguishes Zephrex-D from the competition, but the distinction alone is not adding up to market-share gains in the nonprescription nasal decongestant space.

You may also be interested in...



Extended-Release PSE Points Acura At First Tamper-Resistant Formulation NDA

Like extended-release PSE products already available OTC, a product with tamper-resistant formulation labeling must go through the NDA process. “The novelty of this to the FDA is what testing you do to demonstrate meth resistance … what labeling do you put on a product?” says Acura CEO Bob Jones.

Extended-Release PSE Points Acura At First Tamper-Resistant Formulation NDA

Like extended-release PSE products already available OTC, a product with tamper-resistant formulation labeling must go through the NDA process. “The novelty of this to the FDA is what testing you do to demonstrate meth resistance … what labeling do you put on a product?” says Acura CEO Bob Jones.

Tamper-Resistant PSE Takes Big Pharma Stage: Bayer Licenses Acura’s Formulation

Bayer gains exclusive worldwide license to Acura Pharmaceuticals’ Impede technology for use in a pseudoephedrine-containing product resistant to extraction to make methamphetamine. The deal is Acura’s first licensing, and the first move toward tamper-resistant PSE by a major pharma firm.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS106981

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel